Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

XP 21279

Alternative Names: 279/CD; Levodopa prodrug - Arbor Pharmaceuticals; XP-21279; XP21279/carbidopa

Latest Information Update: 26 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XenoPort
  • Developer Arbor Pharmaceuticals
  • Class Antiparkinsonians; Catecholamines
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 30 Jun 2015 Phase II development is ongoing in USA
  • 30 Jun 2015 XenoPort is still considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/
  • 24 Apr 2013 XenoPort is considering partnering opportunities for the development and commercialisation of XP 21279 outside USA. http://www.xenoport.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now